Intravenous chemotherapy for resected gastric cancer: Meta-analysis of randomized controlled trials

World Journal of Gastroenterology

Volumn 8, Issue 6, 2002, Pages 1023-1028

  Hu, Jian Kun ^a   Chen, Zhi Xin ^a   Zhou, Zong Guang ^a   Zhang, Bo ^a   Tian, Jing ^a   Chen, Jia Ping ^a   Wang, Li ^b   Wang, Chao Hua ^a   Chen, Hong Yan ^a   Li, You Ping ^b  

^a SICHUAN UNIVERSITY   (China)

^b Chinese Evidenced Based Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN C; TEGAFUR; VINBLASTINE;

ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHI SQUARE TEST; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBASE; FOLLOW UP; GASTRECTOMY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTHERMIC THERAPY; INFORMATION PROCESSING; LANGUAGE; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; METHODOLOGY; NAUSEA AND VOMITING; NEUROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RISK; SCORING SYSTEM; SEPTICEMIA; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT PLANNING;

EID: 0036900097     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i6.1023     Document Type: Article

References (91)

1. Wang X, Lan M, Shi YQ, Lu J, Zhong YX, Wu HP, Zai HH, Ding J, Wu KC, Pan BR, Jin JP, Fan DM. Differential display of vincristine-resistance-related genes in gastric cancer SGC7901 cell. World J Gastroenterol 2002; 8: 54-59
2. Zhang XY. Some recent works on diagnosis and treatment of gastric cancer. World J Gastroenterol 1999; 5: 1-3
3. Zou SC, Qiu HS, Zhang CW, Tao HQ. A clinical and long-term follow-up study of peri-operative sequential triple therapy for gastric cancer. World J Gastroenterol 2000; 6: 284-286
4. Li Y, Yang L, Cui JT, Li WM, Guo RF, Lu YY. Construction of cDNA representational difference analysis based on two cDNA libraries and identification of garlic inducible expression genes in human gastric cancer cells. World J Gastroenterol 2002; 8: 208-212
5. Li Y, Lu YY. Applying a highly specific and reproducible cDNA RNA method to clone garlic up-regulated genes in human gastric cancer cells. World J Gastroenterol 2002; 8: 213-216
6. Liu JR, Li BX, Chen BQ, Han XH, Xue YB, Yang YM, Zhengn YM, Liu RH. Effect of cis-9, trans-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line (SGC-7901). World J Gastroenterol 2002; 8: 224-229
7. Tovey FI, Hobsley M. Post-gastrectomy patients need to be followed up for 20-30 years. World J Gastroenterol 2000; 6: 45-48
8. Hou P, Tu ZX, Xu GM, Gong YF, Ji XH, Li ZS. Helicobacter pylori vacA genotypes and cagA status and their relationship to associated diseases. World J Gastroenterol 2000; 6: 605-607
9. Deng DJ. Progress of gastric cancer etiology: N-nitrosamides in the 1990s. World J Gastroenterol 2000; 6: 613-618
10. Yin F, Shi YQ, Zhao WP, Xiao B, Miao JY, Fan DM. Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol 2000; 6: 664-670
11. Cai L, Yu SZ, Ye WM, Yi YN. Fish sauce and gastric cancer: An ecological study in Fujian Province, China. World J Gastroenterol 2000; 6: 671-675
12. Li QF, Ou-Yang GL, Li CY, Hong SG. Effects of tachyplesin on the morphology and ultrastructure of human gastric carcinoma cell line BGC-823. World J Gastroenterol 2000; 6: 676-680
13. Zhu JS, Su Q, Zhou JG, Hu PL, Xu JH. Study of primary leiomyosarcoma induced by MNNG in BALB/C nude mice. World J Gastroenterol 2000; 6: 128-130
14. Cao WX, Cheng QM, Fei XF, Li SF, Yin HR, Lin YZ. A study of preoperative methionine-depleting parenteral nutrition plus chemotherapy in gastric cancer patients. World J Gastroenterol 2000; 6: 255-258
15. Tian XJ, Wu J, Meng L, Dong ZW, Shou C.C. Expression of VEGF121 in gastric carcinoma MGC803 cell line. World J Gastroenterol 2000; 6: 281-283
16. Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujian Province, China. World J Gastroenterol 2000; 6: 374-376
17. Zhang FX Zhang XY, Fan DM, Deng ZY, Yan Y, Wu HP, Fan JJ. Antisence telomerase RNA induced human gastric cancer cell apoptosis. World J Gastroenterol 2000; 6: 430-432
18. Gu QL, Li NL, Zhu ZG, Yin HR, Lin Y.Z. A study on arsenic trioxide inducing in vitro apoptosis of gastric cancer cell lines. World J Gastroenterol 2000; 6: 435-437
19. Wang ZN, Xu HM. Relationship between collagen IV expression and biological behavior of gastric cancer. World J Gastroenterol 2000; 6: 438-439
20. Han FC, Yan XJ, Su CZ. Expression of the CagA gene of H. pylori and application of its product. World J Gastroenterol 2000;6:122-124
21. Chen GY, Wang DR. The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol 2000; 6: 704-708
22. Tuo BG, Yan YH, Ge ZL, Ou GW, Zhao K. Ascorbic acid secretion in the human stomach and the effect of gastrin. World J Gastroenterol 2000; 6: 704-708
23. Huang XQ. Helicobacter pylori infection and gastrointestinal hormones: A review. World J Gastroenterol 2000; 6: 783-788
24. Gao HJ, Yu LZ, Bai JF, Peng JS, Sun G, Zhao HL, Miu K, Lü XZ, Zhang XY, Zhao ZQ. Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions: H. pylori infection, histological types and staging. World J Gastroenterol 2000; 6: 848-854
25. Chen JP, Lin C, Xu CP, Zhang XY, Wu M. The therapeutic effects of recombinant adenovirus RA538 on human gastric carcinoma cells in vitro and in vivo. World J Gastroenterol 2000; 6: 898-901
26. Zhou HP, Wang X, Zhang NZ. Early apoptosis in intestinal and diffuse gastric carcinomas. World J Gastroenterol 2000; 6: 898-901
27. Chen XQ, Zhang WD, Song YG, Zhou DY. Induction of apoptosis of lymphocytes in rat mucosal immune system. World J Gastroenterol 1998; 4: 19-23
28. Xiao B, Shi YQ, Zhao YQ, You H, Wang ZY, Liu XL, Yin F, Qiao TD, Fan DM. Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs. World J Gastroenterol 1998; 4: 421-425
29. Wang XW, Xie H. Presence of Fas and Bcl-2 proteins in BEL-7404 human hepatoma cells. World J Gastroenterol 1998; 4: 540-543
30. Lu Y, Zhao G, Guo CY, Jia SR, Hou YD. Vagus effect on pylorus-preserving gastrectomy. World J Gastroenterol 1999; 5: 177-178
31. Liu HF, Liu WW, Fang DC, Men RP. Expression and significance of proapoptotic gene Bax in gastric carcinoma. World J Gastroenterol 1999; 5: 15-17
32. Li HL, Chen DD, Li XH, Zhang HW, Lu YQ, Ye CL, Ren XD. Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: Role of reactive oxygen species. World J Gastroenterol 2002; 8: 431-435
33. He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H, Zhang LR. Expression, deletion and mutation of p16 gene in human gastric cancer. World J Gastroenterol 2001; 7: 515-521
34. Han Y, Han ZY, Zhou XM, Shi R, Zheng Y, Shi YQ, Miao JY, Pan BR, Fan DM. Expression and function of classical protein kinase C isoenzymes in gastric cancer cell line and its drug-resistant sublines. World J Gastroenterol 2002; 8: 441-445
35. Ji F, Peng QB, Zhan JB, Li YM. Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer. World J Gastroenterol 1999; 5: 152-155
36. Xia L, Yuan YZ, Xu CD, Zhang YP, Qiao MM, Xu JX. Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor nude mice. World J Gastroenterol 2002; 8: 455-458
37. Zhang Z, Yuan Y, Gao H, Dong M, Wang L, Gong YH. Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions. World J Gastroenterol 2001; 7: 779-782
38. Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, Wu LF, Zhu AL, Wang XQ, Wu M. Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol 2002; 8: 580-585
39. Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H.pylori infection with gastric carcinoma: A meta analysis. World J Gastroenterol 2001; 7: 801-804
40. Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Luter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, Bayerd Rffer E. Helicobacter pylori and gastric cancer: Current status of the Austrian Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol 2001; 7: 243-247
41. Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol 2002; 8: 586-590
42. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-595
43. Ren J, Dong L, Xu CB, Pan BR. The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8: 596-601
44. Ren J, Dong L, Xu CB, Pan BR. Expression of sphingosine kinase gene in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8: 602-607
45. Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, Mcardle CS. Evaluation of the prognostic factors in gastric cancer: The effect of chemotherapy on survival. Br J Surg 1987;74:715-720
46. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726-733
47. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van De Velde CJH. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447
48. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309-326
49. Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Santos JGD, Labianca R, Rougier P, Gignoux M. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763
50. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 1994; 343: 1309-1312
51. Estape J, Grau JJ, Lcobendas F, Curto J, Daniels M, Vinolas N, Pera C. Mitomycin C as an adjuvant treatment to resected gastric cancer: A 10-year follow-up. Ann Surg 1991; 213: 219-221
52. Kim JP, Kwon OH, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992;216:269-279
53. Schlag P. Adjuvant chemotherapy in gastric cancer. World J Surg 1987; 11: 473-477
54. Neri B, Leonardis VD, Romano S, Andreoli F, Pernice LM, Bruno L, Borrelli D, Valeri A, Fabbroni S, Intini C, Cini G. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: A multicentre randomised study. Br J Cancer 1996; 73: 549-552
55. Lawton JO, Giles GR, Hall R, Bird GG, Matheson T. Chemotherapy following palliative resection of gastric cancer. Br J Surg 1981; 68: 397-399
56. Cirera L, Balil A, Alentorn EB, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigi E, Guasch I, Badia A, Boleda M. Randomized clinical trial of adjuvant mitomycin plus Tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815
57. Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: Interim report. Br J Cancer 1989; 60: 739-744
58. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British stomach cancer group trial. Lancet 1989; 1: 571-574
59. Yu CCW, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, Hallisey MT. Pathological prognostic factors in the second British stomach cancer group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer 1995; 71: 1106-1110
60. Pignon JP, Ducreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: A critical reappraisal. J Clin Oncol 1994; 12: 877-878
61. Engstrom PF, Lavin PT, Douglass HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 1985; 55: 1868-1873
62. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983; 52: 1105-1112
63. Bonfanti G, Tumori N. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75: 1100-1104
64. Douglass HO, Stablein DM. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116-1122
65. Coombes RC, Schein PS, Chilvers CED, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimalt A, Mefterfle C, Rauschecker HF, Boven F, Vassilopoulos P, Welvaart K, Ferreira EP, Wiig J, Gisselbrecht C, Rougier P, Woods EMA. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-1369
66. Fielding JWL, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, Brookes VS, Craven JL, Mason MC, Timothy A, Waterhouse JAH, Wrigley PFM. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British stomach cancer group. World J Surg 1983;7:390-399
67. Krook JE, O'Connell MJ, Wieand HS, Beart RW, Leigh JE, Kugler JW, Foley JF, Pfeifle DM, Twito DI. A prospective, randomized evaluation of intensive-course 5-Fluorouracil plus Doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458
68. Shimada K, Ajani JA Adjuvant therapy for gastric carcinoma patients in the past 15 years. Cancer 1999; 86: 1657-1668
69. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534
70. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-354
71. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacher J, Rabl H, Holzberger P, Lisborg P, Czeijka M. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 1998; 16: 2733-2738
72. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974
73. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991; 15: 530-536
74. Hagiwara A, Takahashi T, Ueda T, Lee R, Takeda M, Itoh T. Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. Surg 1988; 104: 874-881
75. Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, Kiyabu M, Radin R, Laine L, Stain S, Fuerst M, Groshen S, Donovan A. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A university of Southern California pilot program. J Clin Oncol 1992; 10: 1933-1942
76. Kiyabu M, Leichman L, Chandrasoma P. Effects of preoperative chemotherapy on gastric adenocarcinomas: A morphologic study of 25 cases. Cancer 1992; 70: 2239-2245
77. Ajani JA, Ota DM, Jessup JM, Ames FC, Mcbride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma: An evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-1506
78. Yonemura Y, Sawa T, Konoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T, Fujimura T, Sugiyama K, Shima K, Miyazaki I. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-262
79. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargaves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2403-2411
80. Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, Helmberger A, Bottcher K, Siewert JR. Preoperative chemotherapy for stage III-IV gastric carcinoma: Feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248-1252
81. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W , Lenaz L, Knipp H, Schmoll HJ. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326
82. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-esophageal cancer. Br J Cancer 1996; 74: 1651-1654
83. Sugamura K, Makino M, Shirai H, Kimura O, Maeta M, Itoh H, Kaibara N. Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 1997; 79: 12-17
84. Becker K, Fumagalli U, Mueller JD, Fink U, Siewert JR, Hofler H. Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma. Cancer 1999; 85: 1484-1489
85. Lokich JJ, Shea M, Chaffey J. Sequential influsional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 1987; 60: 275-279
86. Gill PG, Jamieson GG, Denham J, Devitt PG, Ahmad A, Yeoh E, Jones AM. Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy. Br J Surg 1990; 77: 1020-1023
87. Coia LR, Paul AR, Engstrom PF. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer 1988; 61: 643-649
88. Haas CD, Mansfield CM, Leichman LP, Considine B, Bukowski RM. Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, Doxorubicin, and Mitomycin for residual localized gastric adenocarcinoma: A southwest oncology group pilot study. Cancer Treat Rep 1983; 67: 421-424
89. Weissberg JB. Role of radiation therapy in gastrointestinal cancer. Arch Surg 1983; 118: 96-104
90. Tao HQ, Zhou SC. Effect of preoperative regional artery chemotherapy on proliferation and apoptosis of gastric carcinoma cells. World J Gastroenterol 2002; 8: 451-454
91. Cao WX, Ou JM, Fei XF, Zhu ZG, Yin HR, Yan M, Lin YZ. Methionine-dependence and combination chemotherapy on human gastric cancer cells in vitro. World J Gastroenterol 2002; 8: 230-232